Interactions on record — worth a quick check against your medications. Check your meds →
Dietary supplement

Methylene Blue Drops 1% Pharmaceutical Grade Ingredients & Drug Interactions

by Bluesun

Liquid Category: Dietary Supplement
Most serious interaction: Moderate
The interaction bottom line Most serious interaction: Moderate

Methylene Blue Drops 1% Pharmaceutical Grade is a dietary supplement by Bluesun with 1 active ingredient. Its ingredients are commonly taken for methemoglobinemia (a blood disorder), claimed energy or mental focus support, anti-aging or longevity claims.Based on those ingredients, 315 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Methylene Blue. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

HelloPharmacist Scorecard of Methylene Blue Drops 1% Pharmaceutical Grade by Bluesun

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

What’s inside

Full disclosure
Ingredient Transparency · database check
Full

Every active ingredient lists its own amount on the label.

Why this rating?
  • The label discloses an exact amount for 1 of its 1 active ingredient.
  • No proprietary blends here — you can verify the dose of every single component.

Methylene Blue Drops 1% is a single-ingredient liquid product containing one active ingredient: methylene blue, a pharmaceutical-grade compound. One inactive ingredient, Reverse-Vine, is also present in the formulation.

Does it work?

Couldn't assess
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Not assessable

We hold no graded evidence for this product's ingredients for its stated purpose.

Why this rating?
  • The label markets this product for: focus, concentration, cognitive performance, and energy support.
  • Our graded evidence for these ingredients doesn't cover that particular purpose.

No effectiveness data is on file in our records for methylene blue in this product.

The evidence, ingredient by ingredient Methylene Blue

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 1 of the 1 matched ingredient.
  • Pregnancy & breastfeeding safety ratings cover 1 of 1.
  • General safety write-ups exist for 1 of 1.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

Methylene blue is a real drug with real risks and should not be self-dosed casually — it's designed for medical supervision. The product facts note that prescription-grade methylene blue is generally well tolerated when used as prescribed, but it's unclear how supplemental or non-prescription forms may affect side effect risk.

Oral use can cause abdominal pain, blue or green urine, diarrhea, trouble urinating, headache, nausea, and vomiting; less common oral side effects include hemolytic anemia (breakdown of red blood cells) and methemoglobinemia (a blood chemistry problem). Methylene blue should be avoided in pregnancy unless your doctor determines it is necessary, and there isn't enough safety information to recommend it while breastfeeding.

Side effects, ingredient by ingredient Methylene Blue

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 1 of the 1 matched ingredient can interact with medications — Methylene Blue.
  • The most serious interaction on file is rated Moderate.
  • For scale: 315 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

Before taking this product, check with your doctor or pharmacist if you use anticholinergic drugs (Moderate severity) or serotonergic drugs like antidepressants, certain pain relievers, or anti-anxiety medications (Moderate severity). These are the two main medication types with documented interactions to this ingredient.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFully disclosed formula with no assessable stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.

Methylene Blue Drops 1% carries documented Moderate-severity interactions with anticholinergic and serotonergic drugs, and it's a pharmaceutical compound that warrants medical oversight. If you take any prescription medication — especially antidepressants, anti-anxiety drugs, pain medications, or drugs that affect nerve signals — talk with your doctor or pharmacist before using this product.

Pregnant and breastfeeding individuals should discuss it with their healthcare provider.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 1 of 1 active ingredient matched to our full ingredient reviews (monographs). Based on the product label dated Jul 17, 2026.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Methylene Blue Drops 1% Pharmaceutical Grade, straight from the product label.

Brand Bluesun
Net contents 2 Fl Oz (60 mL)
Market status On market
Added to our catalog Jul 17, 2026
Product type Dietary Supplement
Supplement form Liquid
Dietary claims / uses Supports steady daily concentration, Supports peak cognitive performance, Sustained, vibrant energy
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Methylene Blue Drops 1% Pharmaceutical Grade by Bluesun, compiled by our pharmacy team from the manufacturer's label.

Supplement Facts

Daily Value (DV) Target Group(s):
N/A
Minimum serving Sizes:
1 mL (approx 20 drops)
Maximum serving Sizes:
1 mL (approx 20 drops)
Servings per container
60
IngredientAmount% DV
Methylene Blue10 mg--

Other ingredients: Reverse-Vine

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Warnings

This product should be used under the guidance of a healthcare professional. It is not recommended for individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency or those taking serotonergic medications (e.g., SSRIs, SNRIs, MAOIs) due to the risk of serotonin syndrome. It is not suitable for pregnant or breastfeeding women. Common side effects may include blue urine and skin discoloration. Potent blue dye—stains instantly. Blue discoloration of the mouth, teeth, and urine is normal and fades naturally. Please consult your doctor before use.

Suggested Use

Begin with 1-2 drops in your daily beverage to smoothly adapt your body. Gradually adjust your serving size. Consult a healthcare professional to determine the appropriate number of drops for your daily use.

Marketing

Gradually adjust your serving size to support steady, daily concentration.*

Maintain your ideal drop count to support peak cognitive performance.*

Incorporate into your everyday wellness habit for sustained, vibrant energy.*

Other

Statements regarding dietary supplements have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease or health condition.

Allergen Information: Formulated with methylene blue in a pure solution, this product is free from common allergens such as gluten, dairy, and nuts.

See for yourself

Methylene Blue Drops 1% Pharmaceutical Grade by Bluesun label

The product's label imagery, on file with our pharmacy team. Tap to enlarge.

What’s inside

The Ingredients in Methylene Blue Drops 1% Pharmaceutical Grade by Bluesun

This is the 1 active ingredient this product is made of. Select it to open its full monograph.

Serving size1 mL (approx 20 drops) Dosage formLiquid Servings per container60 Amounts shown are per serving.

Methylene Blue

Interacts with
315 drugs
10 mg per serving Form: USP grade, 1% solution in water

Methylene blue is a synthetic dye that is an FDA-approved prescription medicine for a rare blood disorder called methemoglobinemia, and it is also use...

Methylene Blue monograph & interactions

Other (inactive) ingredients: Reverse-Vine. These complete the product’s ingredient list but are not active constituents.

Interaction report

Methylene Blue Drops 1% Pharmaceutical Grade by Bluesun Drug Interactions

Want to check YOUR meds against Methylene Blue Drops 1% Pharmaceutical Grade?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

Go to the checker
315Drugs
315 Moderate

Ingredients driving the most interactions

Each ingredient & the kinds of drugs it affects

For each ingredient in Methylene Blue Drops 1% Pharmaceutical Grade with known interactions, here are the types of medications it can affect. Open any type for the detail — or search your exact drug in the checker above.

Methylene Blue2 drug types · 315 drugs

Anticholinergic Drugs

Concomitant use may increase anticholinergic effects and adverse effects. In a case report, a critically-ill male in his mid-60s developed a toxicological process attributed to anticholinergic syndrome following treatment with methylene blue for vasoplegia. Symptoms included anhidrosis, fever, lactic acidosis, mucosal dryness, and pupil dilation. Potential exacerbating factors included renal failure and use of fentanyl intra-operatively.

Likelihood Possible Evidence D
Serotonergic Drugs

Combining serotonergic drugs with methylene blue can cause additive serotonergic effects, including serotonin syndrome. Methylene blue inhibits monoamine oxidase A. Intravenous or intrapulmonary use has resulted in serotonin syndrome, including reported fatalities, in patients taking some serotonergic drugs. This effect has not been reported with oral methylene blue. However, tell patients to avoid taking methylene blue with serotonergic drugs.

Likelihood Possible Evidence C
The maker

Brand information

Manufacturer and brand details for Methylene Blue Drops 1% Pharmaceutical Grade, from the product label.

Pharmacist Counseling Corner

Methylene Blue Drops 1% Pharmaceutical Grade by Bluesun: Common Questions

Does Methylene Blue Drops 1% Pharmaceutical Grade by Bluesun interact with any medications?
Yes. Based on its ingredients, Methylene Blue Drops 1% Pharmaceutical Grade has a known interaction with 315 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Methylene Blue Drops 1% Pharmaceutical Grade contains a single active ingredient, and that one ingredient can interact with many different medications on its own. We check it against each medication and show the mechanism responsible.
Where does this information come from?
The product label data was compiled by the HelloPharmacist pharmacy team from the manufacturer's product label; the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
What is methylene blue, and why would I take it?
Methylene blue is a pharmaceutical-grade compound — a real drug, not just a supplement. It's used medically under supervision for specific conditions. The product facts don't specify which conditions this particular formulation is intended for, so talk with your doctor or pharmacist about whether it's appropriate for your situation.
Is methylene blue safe to use while I'm pregnant?
No. The safety data advises against methylene blue in pregnancy unless a doctor decides it is medically necessary. If you're pregnant or planning pregnancy, discuss this product with your doctor before using it.
Can I use methylene blue while breastfeeding?
There isn't enough safety information to recommend it while breastfeeding. Talk with your doctor or pharmacist before using this product if you're nursing.
What side effects might I experience if I take this orally?
Oral use can cause abdominal pain, blue or green urine, diarrhea, trouble urinating, headache, nausea, and vomiting. Less common oral side effects include hemolytic anemia and methemoglobinemia (a blood chemistry problem). If you experience any of these, contact your doctor.
Why does the product say methylene blue is 'pharmaceutical grade'?
It means this is a real drug formulation, not a supplement, and it carries real risks. The product facts emphasize it should not be self-dosed casually and needs medical supervision — that's why talking with your doctor or pharmacist before starting is so important.
What if I'm taking an antidepressant — should I avoid this?
Methylene blue interacts with serotonergic drugs (many antidepressants, some pain and anti-anxiety medications, and others). The interaction can cause additive serotonin effects and rarely serotonin syndrome. Don't stop or start either one on your own — talk with your doctor or pharmacist first about whether you can use them together.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Methylene Blue Drops 1% Pharmaceutical Grade is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Methylene Blue Drops 1% Pharmaceutical Grade label
Go deeper

The Full Monographs Behind Methylene Blue Drops 1% Pharmaceutical Grade’s Ingredients

Every ingredient we hold a full HelloPharmacist monograph for — uses, evidence, safety, and the complete interaction list.

Sources

Sources & How We Checked

Methylene Blue Drops 1% Pharmaceutical Grade's label data was compiled by the HelloPharmacist pharmacy team from the manufacturer's product label; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 60 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Methylene Blue 60 references
  1. Chebolu E, Gnirke M, St Francis H, Soghoian S, Su MK. Extravasation with methylthioninium chloride. Clin Toxicol (Phila) 2024;62(11):776-778. PubMed
  2. Walter-Sack I, Rengelshausen J, Oberwittler H, et al. High absolute bioavailability of methylene blue given as an aqueous oral formulation. Eur J Clin Pharmacol. 2009;65(2):179-89. PubMed
  3. Akazawa M, Wu YH, Liu WM. Allergy-like reactions to methylene blue following laparoscopic chromopertubation: A systematic review of the literature. Eur J Obstet Gynecol Reprod Biol 2019;238:58-62. PubMed
  4. Aldeghaither S, Deschênes PJF, Samoukovic G. Anticholinergic Toxidrome as a Possible Explanation for Methylene Blue Toxicity. Am J Case Rep 2023;24:e941453. PubMed
  5. Liao YP, Hung DZ, Yang DY. Hemolytic anemia after methylene blue therapy for aniline-induced methemoglobinemia. Vet Hum Toxicol 2002;44(1):19-21.
  6. Bilgin H, Ozcan B, Bilgin T. Methemoglobinemia induced by methylene blue pertubation during laparoscopy. Acta Anaesthesiol Scand 1998;42(5):594-5. PubMed
  7. Kirlangitis JJ, Middaugh RE, Zablocki A, Rodriquez F. False indication of arterial oxygen desaturation and methemoglobinemia following injection of methylene blue in urological surgery. Mil Med 1990;155(6):260-2. DOI
  8. Porat R, Gilbert S, Magilner D. Methylene blue-induced phototoxicity: an unrecognized complication. Pediatrics 1996;97(5):717-21. DOI
  9. Honoré PJ, Deianova N, Loret G, Hemelsoet D. An easily overlooked cause of toxic encephalopathy: methylene blue in a patient on an SSRI. Acta Neurol Belg 2018;118(1):121-122. PubMed
  10. McRobb CM, Holt DW. Methylene blue-induced methemoglobinemia during cardiopulmonary bypass? A case report and literature review. J Extra Corpor Technol 2008;40(3):206-14. DOI
  11. Donaldson CJ, Sequeira Campos M, El-Sayed M. Inadvertent foetal exposure to methylene blue in the first trimester. J Obstet Gynaecol 2020;40(4):573-574. PubMed
  12. Vanhinsbergh L, Uthaya S, Bain BJ. Methylene blue-induced Heinz body hemolytic anemia in a premature neonate. Am J Hematol 2018;93(5):716-717.
  13. Repici A, Di Stefano AF, Radicioni MM, Jas V, Moro L, Danese S. Methylene blue MMX tablets for chromoendoscopy. Safety tolerability and bioavailability in healthy volunteers. Contemp Clin Trials 2012;33(2):260-7. PubMed
  14. Lee DC, Valente JH. Methylene blue dye-induced knee effusion. Am J Emerg Med 1999;17(7):739-40. PubMed
  15. Albert M, Lessin MS, Gilchrist BF. Methylene blue: dangerous dye for neonates. J Pediatr Surg 2003;38(8):1244-5. PubMed
  16. Giladi AM, Kasten SJ. Anaphylactic-like reaction to methylene blue: case report and review of perioperative hypersensitivity reactions. Plast Reconstr Surg 2012;130(1):98e-105e. PubMed
  17. Bleicher RJ, Kloth DD, Robinson D, Axelrod P. Inflammatory cutaneous adverse effects of methylene blue dye injection for lymphatic mapping/sentinel lymphadenectomy. J Surg Oncol 2009;99(6):356-60. PubMed
  18. George M. Methylene-blue-induced hyperbilirubinemia and phototoxicity in a neonate. Clin Pediatr (Phila) 2000;39(11):659-61.
  19. Lam CW, Wong SY. A case of green urine due to a traditional Chinese medicine containing methylene blue. N Z Med J 2010;123(1312):71-6.
  20. Teknos D, Ramcharan A, Oluwole SF. Pulmonary edema associated with methylene blue dye administration during sentinel lymph node biopsy. J Natl Med Assoc 2008;100(12):1483-4. PubMed
  21. Huang WH, Li MJ. Postoperative Serotonin Syndrome Following Administration of Preoperative Intrapulmonary Methylene Blue and Intraoperative Granisetron: A Case Report. Am J Case Rep 2022;23:e936317. PubMed
  22. Basta MN. Postoperative Serotonin Syndrome Following Methylene Blue Administration for Vasoplegia After Cardiac Surgery: A Case Report and Review of the Literature. Semin Cardiothorac Vasc Anesth 2021;25(1):51-56. PubMed
  23. Gilbert B, Akamune IE. A Case of Serotonin Syndrome Caused by the Concomitant Utilization of Methylene Blue and Venlafaxine in an Oncological Patient. J Pharm Pract 2020;33(5):705-707. PubMed
  24. Hashmi AT, Gupta SS, Shankar S, Seneviratne C, Yoon TS, Kupfer Y. Life-Threatening Serotonin Syndrome Due to Methylene Blue-Citalopram Interaction. Am J Ther 2019;26(6):e740-e741. PubMed
  25. Pelletier JP, Transue S, Snyder EL. Pathogen inactivation techniques. Best Pract Res Clin Haematol. 2006;19(1):205-42. PubMed
  26. Francescangeli J, Vaida S, Bonavia AS. Perioperative Diagnosis and Treatment of Serotonin Syndrome Following Administration of Methylene Blue. Am J Case Rep 2016;17:347-51. PubMed
  27. Hencken L, To L, Ly N, Morgan JA. Serotonin Syndrome Following Methylene Blue Administration for Vasoplegic Syndrome. J Card Surg 2016;31(4):208-10. PubMed
  28. Wolvetang T, Janse R, Ter Horst M. Serotonin Syndrome After Methylene Blue Administration During Cardiac Surgery: A Case Report and Review. J Cardiothorac Vasc Anesth 2016;30(4):1042-5. PubMed
  29. Smith CJ, Wang D, Sgambelluri A, Kramer RS, Gagnon DJ. Serotonin syndrome following methylene blue administration during cardiothoracic surgery. J Pharm Pract 2015;28(2):207-11. PubMed
  30. Top WM, Gillman PK, de Langen CJ, Kooy A. Fatal methylene blue associated serotonin toxicity. Neth J Med 2014;72(3):179-81.
  31. McDonnell AM, Rybak I, Wadleigh M, Fisher DC. Suspected serotonin syndrome in a patient being treated with methylene blue for ifosfamide encephalopathy. J Oncol Pharm Pract 2012;18(4):436-9. PubMed
  32. Grubb KJ, Kennedy JL, Bergin JD, Groves DS, Kern JA. The role of methylene blue in serotonin syndrome following cardiac transplantation: a case report and review of the literature. J Thorac Cardiovasc Surg 2012;144(5):e113-6. PubMed
  33. Sanei ZS, Shahrahmani F, Khaleghi Manesh B, et al. Methylene blue for COVID-19 ARDS: insights from a randomized Clinical Trial. Naunyn Schmiedebergs Arch Pharmacol 2025;398(2):1915-1924. PubMed
  34. Hamidi-Alamdari D, Hafizi-Lotfabadi S, Bagheri-Moghaddam A, et al. METHYLENE BLUE FOR TREATMENT OF HOSPITALIZED COVID-19 PATIENTS: A RANDOMIZED, CONTROLLED, OPEN-LABEL CLINICAL TRIAL, PHASE 2. Rev Invest Clin 2021;73(3):190-198. PubMed
  35. Alamdari DH, Moghaddam AB, Amini S, et al. Application of methylene blue -vitamin C -N-acetyl cysteine for treatment of critically ill COVID-19 patients, report of a phase-I clinical trial. Eur J Pharmacol 2020;885:173494. PubMed
  36. Guo X, Ding W, Liu L, Yang S. Intradiscal Methylene Blue Injection for Discogenic Low Back Pain: A Meta-Analysis. Pain Pract 2019;19(1):118-129. PubMed
  37. Deng M, Huang H, Ma YG, Zhou Y, Chen Q, Xie P. Intradiskal Injection of Methylene Blue for Discogenic Back Pain: A Meta-Analysis of Randomized Controlled Trials. J Neurol Surg A Cent Eur Neurosurg 2021;82(2):161-165. PubMed
  38. Farrokhi MR, Lotfi M, Masoudi MS, Gholami M. Effects of methylene blue on postoperative low-back pain and functional outcomes after lumbar open discectomy: a triple-blind, randomized placebo-controlled trial. J Neurosurg Spine 2016;24(1):7-15. View abstra PubMed
  39. Wilcock GK, Gauthier S, Frisoni GB, et al. Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial. J PubMed
  40. Rodriguez P, Zhou W, Barrett DW, et al. Multimodal Randomized Functional MR Imaging of the Effects of Methylene Blue in the Human Brain. Radiology 2016;281(2):516-526. PubMed
  41. Rodriguez P, Singh AP, Malloy KE, et al. Methylene blue modulates functional connectivity in the human brain. Brain Imaging Behav 2017;11(3):640-648. PubMed
  42. Wischik CM, Staff RT, Wischik DJ, et al. Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease. J Alzheimers Dis 2015;44(2):705-20. PubMed
  43. Baddeley TC, McCaffrey J, Storey JM, et al. Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease. J Pharmacol Exp Ther 2015;352(1):110-8. PubMed
  44. Alda M, McKinnon M, Blagdon R, et al. Methylene blue treatment for residual symptoms of bipolar disorder: randomised crossover study. Br J Psychiatry 2017;210(1):54-60. PubMed
  45. Zhang Z, Zhu Z, Liu H, Chen J, Jin C, Zhang X. A Prospective, Randomized, Controlled Trial of Methylene Blue Injection for Costal Cartilage Harvest Postoperative Analgesia. Aesthet Surg J 2025;45(2):NP65-NP70. PubMed
  46. Soliman M, Salah M, Fadel M, Nasr M, El-Azab H. Contrasting the efficacy of pulsed dye laser and photodynamic methylene blue nanoemulgel therapy in treating acne vulgaris. Arch Dermatol Res 2021;313(3):173-180. PubMed
  47. Alves RO, Urzedo LOR, de Toledo PTA. Antimicrobial Photodynamic Therapy in Onychomycosis Management: A Systematic Review of Clinical Trials. Photodiagnosis Photodyn Ther. 2025:104640. PubMed
  48. Naylor GJ, Martin B, Hopwood SE, Watson Y. A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis. Biol Psychiatry 1986;21(10):915-20.
  49. Telch MJ, Bruchey AK, Rosenfield D, et al. Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia. Am J Psychiatry 2014;171(10):1091-8. PubMed
  50. Jia W, Li Q, Ni J, Zhang Y, Wu L, Xu L. Efficacy and safety of methylene blue injection for intractable idiopathic pruritus ani: a single-arm metaanalysis and systematic review. Tech Coloproctol 2023;27(10):813-825. PubMed
  51. Xue H, Thaivalappil A, Cao K. The Potentials of Methylene Blue as an Anti-Aging Drug. Cells 2021;10(12):3379. PubMed
  52. Wickramasinghe D, Wickramasinghe N, Samarasekera N, Warusavitarne J. The effect of local infiltration of methylene blue on posthemorrhoidectomy pain: A systematic review and meta-analysis. Curr Probl Surg 2025;67:101752. PubMed
  53. Gureev AP, Sadovnikova IS, Popov VN. Molecular Mechanisms of the Neuroprotective Effect of Methylene Blue. Biochemistry (Mosc) 2022;87(9):940-956. PubMed
  54. Isaev NK, Genrikhs EE, Stelmashook EV. Methylene blue and its potential in the treatment of traumatic brain injury, brain ischemia, and Alzheimer's disease. Rev Neurosci 2024;35(5):585-595. PubMed
  55. Tariq B, Simon SR, Pilz W, Maxim A, Kremer B, Baijens LWJ. Evaluating the safety of oral methylene blue during swallowing assessment: a systematic review. Eur Arch Otorhinolaryngol 2021;278(9):3155-3169. PubMed
  56. US Food and Drug Administration (FDA). PROVAYBLUE® (methylene blue) Prescribing Information. January 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/204630s021lbl.pdf. Accessed July 16, 2025
  57. Gauthier S, Feldman HH, Schneider LS, et al. Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet. 2016;388(10062):2873- PubMed
  58. Lu G, Nagbanshi M, Goldau N, et al. Efficacy and safety of methylene blue in the treatment of malaria: a systematic review. BMC Med. 2018;16(1):59. PubMed
  59. Pelgrims J, De Vos F, Van den Brande J, et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000;82(2):291-4. PubMed
  60. Khokhar RS, Aqil M, Al-Zahrani T, Gelidan A, Al Khayal K. Novel management of methylene blue extravasation: A case report and review of literature. Saudi J Anaesth. 2015;9(2):211-3. PubMed

See these in context on the Methylene Blue monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring